enGene Therapeutics (ENGN) Total Current Liabilities (2022 - 2026)

enGene Therapeutics (ENGN) has 5 years of Total Current Liabilities data on file, last reported at $27.2 million in Q3 2026.

• For the quarter ending Q3 2026, Total Current Liabilities rose 33.12% year-over-year to $27.2 million; the trailing twelve-month figure through Jul 2026 stood at $27.2 million (up 33.12% YoY), and the FY2025 full-year result was $32.0 million, up 118.12% from the prior year.
• Total Current Liabilities was $27.2 million for Q3 2026 at enGene Therapeutics, up from $21.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $32.0 million in Q4 2025 to a low of $5.1 million in Q4 2022.
• A 5-year average of $16.0 million and a median of $14.7 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities grew 3.0% in 2023 and soared 185.78% in 2025, its largest moves.
• enGene Therapeutics' Total Current Liabilities stood at $5.1 million in 2022, then gained by 3.0% to $5.3 million in 2023, then jumped by 178.89% to $14.7 million in 2024, then surged by 118.12% to $32.0 million in 2025, then decreased by 14.92% to $27.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $27.2 million in Q3 2026, $21.5 million in Q2 2026, and $24.6 million in Q1 2026.